The company has a commercial pharmaceutical product, POSIMIR (bupivacaine solution), a non-opioid analgesic utilizing the SABER platform technology. As of September 2025, DURECT operates as a subsidiary of Bausch Health Americas with $12M in cash reserves and has shifted focus to advancing Larsucosterol with a Phase 3 trial estimated at $20M.
Cyborg Score Rationale
The company achieved debt-free status and reduced R&D expenses significantly from $29.4M to $10.4M, but 2024 revenue declined to $2M from $2.6M. Analyst price targets were decreased 25.93% to $5.10, with forecasts ranging from $5.05 to $5.25. Commercial traction remains limited while clinical progression on Larsucosterol offers potential upside.
Top Insights
Larsucosterol has received FDA Fast Track and Breakthrough Therapy designations for alcoholic hepatitis, accelerating potential approval pathway
Company eliminated debt and reduced operating expenses by 65% in R&D, extending runway to Q3 2025 with strategic focus on advancing lead program
Subsidiary relationship with Bausch Health may provide financial and operational support for Phase 3 trial execution
Stock volatility increased from 36% to 68% weekly over the past year, indicating significant price instability
Named Competitors
Selonsertib — ASK1 inhibitor for fibrosis/cirrhosis (development stage)
Resmetirom — Thyroid hormone receptor beta agonist for MASH
FibroGenesis Pipeline — Anti-fibrotic compounds for liver disease
Recent Developments
(Sep 2025) Became subsidiary of Bausch Health Americas, Inc.
(2024) Achieved debt-free status after repaying term loan
(2024) Shifted development focus entirely to Larsucosterol for alcohol-associated hepatitis with Phase 3 trial planned
Open the full interactive DURECT Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.